Invivyd Appoints Jeremy Gowler as Chief Operating and Commercial Officer, Promotes Pete Schmidt, M.D., to Chief Medical Officer
06 Dezember 2022 - 10:01PM
Invivyd, Inc. (Nasdaq: IVVD), a clinical-stage biopharmaceutical
company on a mission to protect humanity from serious viral
respiratory diseases, today announced the appointment of Jeremy
Gowler as chief operating and commercial officer, effective
December 16, 2022, and the promotion of Pete Schmidt, M.D. to chief
medical officer, effective immediately.
In his new role Mr. Gowler will oversee operations and
commercial activities for the company. Dr. Schmidt will be
responsible for overseeing all medical, clinical development and
regulatory activities at Invivyd. Dr. Ellie Hershberger, Invivyd’s
chief development officer, is departing from the Company, but is
anticipated to provide consulting services for development
activities.
Mr. Gowler brings 20 years of experience across multiple key
commercialization functions throughout the product lifecycle and
experience in business development. Prior to joining Invivyd, he
has served as the commercial global head of the biopharma business
unit of Sandoz, where he was responsible for late-stage clinical
trial launches and global product commercialization across their
portfolio. Before his time at Sandoz, he held multiple senior
commercial roles across the pharmaceutical and biotechnology
industry. Mr. Gowler received his Diploma of Technology from The
British Colombia Institute of Technology and a B.S. in biology and
environmental studies from the University of Victoria.
“Jeremy is a proven leader in the biopharma industry and will be
a valued partner to me and to our executive team. His expertise
will strengthen Invivyd as we continue to advance our
pipeline and will be instrumental in advancing our business
priorities,” said David Hering, Invivyd CEO and director.
Dr. Schmidt has served as Invivyd’s vice president of clinical
research for the past two years where he was central in advancing
adintrevimab into clinical trials. Prior to joining Invivyd, Dr.
Schmidt worked in academic research and therapeutics development
for neurology, pain, and respiratory products. He is an assistant
clinical professor in the Division of Pain Medicine at the Stanford
University School of Medicine. He received a B.A. in Psychology
from Cornell University, an MSc in Epidemiology and Clinical
Research from Stanford University and an M.D. from the University
of Colorado School of Medicine.
“I am honored to continue working with the team at Invivyd as we
advance our pipeline of monoclonal antibodies against COVID-19 and
other respiratory illnesses,” said Dr. Schmidt. “I feel
particularly passionate about addressing the unmet needs of
vulnerable populations who are currently facing the worst season of
respiratory viruses in recent memory.”
“Pete has been outstanding for this organization, and I am
extremely confident that those efforts will be duplicated and
exceeded in his new role,” said Hering. “His unique skillset will
allow us to seamlessly consolidate the CMO and CDO roles. I would
also like to thank Ellie Hershberger for her significant
contributions to Invivyd over the past several years, including
establishing a strong development team. With Jeremy and Pete’s
broad experience and capabilities, we are maximizing resources and
remaining laser focused on key priorities. I am extremely excited
to add two professionals with their credentials to our leadership
team.”
About Invivyd(Nasdaq: IVVD)Invivyd, Inc.
formerly Adagio Therapeutics (Nasdaq: ADGI), is a
biopharmaceutical company on a mission to protect humanity from
serious viral respiratory diseases. The company is developing
antibodies to transcend the limits of naturally occurring immunity
and provide superior protection from viral diseases, beginning
with COVID-19. Invivyd’s technology works at the intersection
of evolutionary virology, predictive modeling, and
antibody engineering, and is designed to identify
high-quality, long-lasting antibodies with a high barrier to viral
escape. The company is generating a robust pipeline of products
for use in both prevention and treatment of disease. NVD200,
Invivyd’s first antibody combination product candidate for the
prevention and treatment of COVID-19, includes a re-engineered
version of adintrevimab, an investigational monoclonal antibody
which demonstrated clinically meaningful results against multiple
variants of concern in global Phase 2/3 clinical trials for the
prevention and treatment of COVID-19, prior to the emergence of
Omicron. The safety and efficacy of adintrevimab have not been
established. The company also has multiple discovery stage
candidates for the prevention of seasonal influenza.
Visit www.invivyd.com to learn more.Cautionary
Note Regarding Forward Looking StatementsThis press
release contains forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995. Words such as
“anticipates,” “believes,” “could,” “expects,” “intends,”
“potential,” “projects,” and “future” or similar expressions (as
well as other words or expressions referencing future events,
conditions or circumstances) are intended to identify
forward-looking statements. Forward-looking statements include
statements concerning, among other things, the implementation and
impact of the management changes and consolidation and the intended
benefits to the company from the changes; the future of the
COVID-19 landscape including the expectation of continued evolution
and emergence of new variants and subvariants; our ongoing research
and clinical development plans and the timing thereof; our plans to
advance adintrevimab, NVD200, or other early stage candidates as a
potential prophylaxis and treatment option for COVID-19, including
disease caused by most variants, as either a single or combination
agent, including our intention to initiate clinical development of
NVD200 in the first quarter of 2023; the potential for adintrevimab
and NVD200 to demonstrate activity against predominant SARS-CoV-2
variant(s) in the U.S. and globally; our plans, technology and
resources to develop therapeutic or preventative options for other
infectious diseases, such as additional coronaviruses and seasonal
influenza, in the U.S. and globally; and other statements that are
not historical fact. We may not actually achieve the plans,
intentions or expectations disclosed in our forward-looking
statements and you should not place undue reliance on our
forward-looking statements. These forward-looking statements
involve risks and uncertainties that could cause our actual results
to differ materially from the results described in or implied by
the forward-looking statements, including, without limitation: we
may not realize anticipated benefits from the management changes
and consolidation; potential disruptions to the business as a
result of management transitions; the impacts of the COVID-19
pandemic on our business and those of our collaborators, our
clinical trials and our financial position; unexpected safety or
efficacy data observed during preclinical studies or clinical
trials; the predictability of clinical success of adintrevimab,
NVD200, or other pipeline candidates or combination of candidates
based on neutralizing activity in pre-clinical studies; variability
of results in models used to predict activity against SARS-CoV-2
variants of concern; clinical trial site activation or enrollment
rates that are lower than expected; changes in expected or existing
competition; changes in the regulatory environment; the
uncertainties and timing of the regulatory approval process,
including the outcome of our discussions with regulatory
authorities concerning our clinical trials; whether adintrevimab,
NVD200, or any other pipeline candidate or combination of
candidates is able to demonstrate activity against predominant
SARS-CoV-2 variant(s) in the U.S. and globally; whether we are able
to successfully submit an emergency use authorization in the
future, and the outcome of any such emergency use authorization
submission; whether research and development efforts will improve
efficacy of adintrevimab against predominant variants or identify
additional monoclonal antibodies or combination of antibodies for
the prevention and treatment of COVID-19 and other infectious
diseases; whether research and development efforts will identify
and result in safe and effective therapeutic or preventative
options for other infectious diseases in the U.S. or globally and
whether we have adequate funding to meet future operating expenses
and capital expenditure requirements. Other factors that may cause
our actual results to differ materially from those expressed or
implied in the forward-looking statements in this press release are
described under the heading “Risk Factors” in our Annual Report on
Form 10-K for the year ended December 31, 2021 and our Quarterly
Report on Form 10-Q for the quarter ended September 30, 2022, each
filed with the Securities and Exchange Commission (the “SEC”), and
in our other filings with the SEC, and in Invivyd’s future reports
to be filed with the SEC and available at www.sec.gov. Such risks
may be amplified by the impacts of the COVID-19 pandemic.
Forward-looking statements contained in this press release are made
as of this date, and Invivyd undertakes no duty to update such
information whether as a result of new information, future events
or otherwise, except as required under applicable law.
This press release contains hyperlinks to information that is
not deemed to be incorporated by reference in this press
release.
Media Contact: Tony Berry, Evoke
Canale 774-317-0422 anthony.berry@evokegroup.com
Investor Contact:Chris Brinzey, ICR
Westwicke339-970-2843chris.brinzey@westwicke.com
Adagio Therapeutics (NASDAQ:ADGI)
Historical Stock Chart
Von Aug 2024 bis Sep 2024
Adagio Therapeutics (NASDAQ:ADGI)
Historical Stock Chart
Von Sep 2023 bis Sep 2024